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Introduction and background: Vitamin D deﬁciency has been associatedwith cardiovascular diseases (CVDs) and its
surrogate indicators such as endothelial dysfunction. It is an independent predictor of CVDs and all-causemortality.
Methods:We review the updated literature surrounding vitamin D and the endothelium spanning molecular,
translational and clinical studies including randomized controlled trials (RCTs). We review the possible actions
of vitamin D on the quiescent and activated endothelium including lessons from animal models. We review
the recent literature for association of Vitamin D deﬁciency with endothelial dysfunction and cardiovascular
complications, and for clinical trials done to look at the effect of vitamin D supplementation on the endothelium
and cardiovascular outcome.
Results and conclusion: Vitamin D deﬁciency is associated with endothelial dysfunction and cardiovascular
diseases. Vitamin D stabilizes the quiescent endothelium, modulates certain stages of endothelial activation,
and is involved in the repair of the damaged endothelium in vitro and in vivo. Twelve recent cross sectional
studies, including 2086 subjects of varying ethnic groups, show an association between endothelial dysfunction
and vitamin D deﬁciency. Yet 10 recent RCTs of vitamin D supplementation involving 824 subjects have failed to
show signiﬁcant improvements in endothelial function in the short term. So far, RCTs have not been able to
conﬁrm or refute the beneﬁt of vitamin D supplementation on vascular mortality. Longer term randomized
controlled trials using doses of vitamin D to optimize serum 25(OH)D concentrations to 20.0–40.0 ng/mL
(50.0–100.0 nmol/L) or using vitamin D analogues with no calciotropic effects are needed to assess endothelial
function and cardiovascular outcomes.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cardiovascular disease (CVD) remains the leading cause of
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tion and CVD. Vitamin D deﬁciency has recently been found to be more
prevalent than previously suspected. It has attracted recent attention
for its potential cardio-protective properties especially its actions on
the endothelium. Although there has been signiﬁcant updates on the
possible mechanisms of action of vitamin D, the exact mechanism by
which vitamin D may inﬂuence the atherosclerotic process has not yet
been completely elucidated. Large scale, well conducted, placebo con-
trolled clinical trials testing the efﬁcacy of vitamin D supplementation
in delaying, slowing or reverting the atherosclerotic process have not
yet been conducted.
The aim of this review is to review the available literature for the
possible role and actions of vitaminDon the endotheliumand summarize
the pathobiology of vitaminDdeﬁciency and endothelial dysfunction.We
also review the recent literature looking at 12 cross-sectional studies
(2086 subjects) showing an association of vitamin D deﬁciency with en-
dothelial dysfunction. A review of 15 recent randomized controlled trials
(1041 subjects) is also presented to see whether supplementation helps
in improvement of endothelial function. Recent epidemiological evidence,
inclusive of recently published meta-analyses, looking at vitamin D
deﬁciency and cardiovascular mortality is presented as well.
2. Vitamin D
Vitamin D is a fat soluble vitamin with two dominant forms,
vitamins D2 (ergocalciferol) and D3 (cholecalciferol). Vitamin D2 is
synthesized by invertebrates and plants after exposure to ultraviolet
radiation [3]. Vitamin D3 is naturally present in a small range of foods
(such as oily ﬁsh, egg and fortiﬁed dairy products) and is also made en-
dogenously in the skin. Dietary vitaminD typically comprises only 10.0%
to 20.0% of circulating levels of vitamin D. These two vitamins are simi-
lar and differ chemically only in their side chains. This difference alters
their binding to vitamin D binding protein (DBP) and their metabolism
[4]. Recently, it has been seen that D3 is signiﬁcantlymore effective than
D2 in increasing serum 25(OH) vitamin D (25(OH)D) concentrations
[5–7]. Hence, based on differences in their efﬁcacy at raising serum
25(OH)D, diminished binding of vitamin D2metabolites to DBP in plas-
ma, a non-physiological metabolism and a shorter shelf life of vitamin
D2, vitamin D3 is considered to be a better form of supplementation
[8]. It has been reported that in patients with normal gastrointestinalFig. 1. 1. In daylight hours, under the inﬂuence of solar UV radiation on the skin, 7-dehydrochole
to get converted to tachysterol and then lumisterol which continues to accumulate with contin
because of the photo-conversion of pro-D3 to lumisterol and tachysterol and other inactive m
converted back to pro-D3. 4. Pro-D3 gets converted to D3 over time. 5. The formed D3 binds toabsorptive capacity, for every 100 IU/day of vitamin D3, serum 25(OH)
D concentrations increase by approximately 1 ng/mL (2.5 nmol/L) [9,
10]. Largest increments are seen in patients with the lowest starting
25(OH)D concentrations, but subsequently decline as 25(OH)D concen-
trations reach 40 ng/ml (100 nmol/L) [11]. The serum 25(OH)D
response to supplementation also depends on genetic variability, BMI,
self reported health status and ambient UV radiation [12,13]. Nutritional
deﬁciency (25(OH)D concentrations b 20 ng/mL) requires initial
treatment with 50,000 IU of vitamin D2 or D3 orally once per week for
6–8 weeks and then 800–1000 IU of vitamin D3 orally as maintenance
therapy [14]) and the Endocrine Society USA recommends a dose of
Vitamin D3 6000 IU daily in patients with nutritional deﬁciency to
achieve serum 25(OH)D concentrations of N 30 ng/mL in 6–8 weeks
and to continue maintenance doses of 2000 U daily thereafter [15].
In daylight hours, vitamin D3 is photosynthesized endogenously in
the skin when 7-dehydrocholesterol (pro-vitamin D3), a zoosterol
most concentrated in the stratum spinosum and stratum basale of the
epidermis, is exposed to solar ultraviolet B (UVB) radiation between
wavelengths of 290 and 320 nm, with peak synthesis occurring within
295 and 297 nm (Fig. 1). Photolysis of 7-dehydrocholesterol into
pre-vitamin D3 via an electrocyclic reaction occurs rapidly, following
which the latter undergoes thermal isomerization through a
sigmatropic hydride shift into vitamin D3. Within 15–30 min of whole
body sunlight exposure, 10,000 to 20,000 IU of vitamin D3 is produced.
Once maximum levels are reached in a few hours, it starts to get
converted to tachysterol and then lumisterol which continues to accu-
mulate with continued UV exposure. Prolonged exposure to sunlight
would not produce toxic amounts of vitamin D3 because of the photo-
conversion of pre-D3 to lumisterol and tachysterol and photo-
degradation into other inactive metabolites such as 5,6-trans-vitamin
D3, suprasterol 1 and suprasterol 2. Subsequently under dark conditions
and as pre-D3 declines, lumisterol and tachysterol can undergo revers-
ible conversion back to pre-D3. The formed vitaminD3 binds toDBP and
is transported in the blood in this bound form (Fig. 2) [16].
Excessive oral supplementation of Vitamin D can lead to toxicity as
widespread vitamin D fortiﬁcation of foods and drinks from 1930s to
1950s in the United States and Europe led to reported cases of toxicity
[17]. This is because Vitamin D supplementation raises plasma 25(OH)
D concentrations that exceed DBP binding capacity, and free 25(OH)D
concentrations have direct effects on gene expression once it enterssterol is converted to Pro-D3. 2. Oncemaximum levels are reached in a few hours, it starts
ued UV exposure. Prolonged exposure to sunlight would not produce toxic amounts of D3
etabolites. 3. Subsequently under dark conditions and as pro-D3 declines, lumisterol gets
vitamin D binding protein and is transported in the blood in this bound form.
Fig. 2. 1. The exogenously acquired vitamin D undergoes the ﬁrst biological activation in the liver, where the vitamin D is converted to 25(OH)D by cytochrome P-450 vitamin D
25-hydroxylase enzyme. 2. Subsequently 25(OH)D is converted to 1α,25(OH)2D3 in the kidneys by the enzyme cytochrome P-450 monooxygenase 25(OH)D 1-alpha hydroxylase.
3. This second step also occurs at extra renal sites such as skin cells, monocytes/macrophages, placenta during pregnancy, prostate and even the endothelium. 4. The unbound active
form thus produced can enter target cells and interact with the ligand-binding domain of a speciﬁc nuclear receptor (VDR) leading to heterodimer formation with RXR and downstream
activation of VDREs and subsequent transcription of proteins for the genomic actions. 5. The active formmay also ligand in the caveolae with the plasmamembrane VDR to generate non
genomic rapid responses. The rapid responses include activation of one ormore secondmessenger systems (e.g. phospholipase C, protein kinase C, etc.). Some of these secondmessengers
can cross talk with the nucleus to modulate gene expression.
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tions of many vitamin D metabolites including vitamin D itself and
25(OH)D, and these concentrations exceed the DBP binding capacity
and release free 1,25(OH)D which enters the target cells [18]. Hence
vitamin D supplementation must be accompanied with monitoring
of 25(OH)D concentrations to keep it within the optimal range of
30–50 ng/mL (75–125 nmol/L).
Vitamin D requires two hydroxylation reactions in the body for bio-
logical activation [19]. The ﬁrst biological activation occurs in the liver,
where vitaminD is converted to 25(OH)D by cytochromeP-450 vitamin
D 25-hydroxylase enzyme. 25(OH)D is converted to 1α,25(OH)2D3 in
the kidneys by the enzyme cytochrome P-450 monooxygenase
25(OH)D 1-alpha hydroxylase [19]. This process also occurs at extra-
renal sites such as skin cells, monocytes/macrophages, placenta during
pregnancy, colon cells, endothelial cells, mammary (breast) cells, pan-
creatic islets and prostate cells. This ﬁnding is based on the presence
of 25(OH)D 1-alphahydroxylase enzyme, detection ofmRNA for the en-
zyme and the presence of measurable enzyme activity in these tissues
[20]. The unbound active form thus produced can enter target cells
and interact with the ligand-binding domain of a speciﬁc nuclear recep-
tor, the vitamin D receptor (VDR). The active vitamin D produced at
extra-renal sites act in a paracrine/autocrine fashion to regulate cell
growth and differentiation (Fig. 2) [19]. In humans, the VDR is encoded
by the VDR gene [21]. 1α,25(OH)2D3 interacts with the VDR localized in
the cell nucleus to generate genomic responses and in the caveolaewith
the plasma membrane VDR to generate rapid responses. The rapidresponses include activation of one or more secondmessenger systems
(e.g. phospholipase C, protein kinase C, etc.). Some of these secondmes-
sengers cross talk with the nucleus to modulate gene expression [20].
Upon activation by vitamin D, the nuclear VDR forms a heterodimer
with the retinoid X receptor (RXR). The VDR–RXR heterodimer then
binds to direct repeat vitaminD responsive elements (VDREs) upstream
of positively controlled genes in the nucleus of the target cells [22]. The
VDR for the steroid hormone 1α,25(OH)2D3 is located in up to 36 target
organs, including the skin, endothelium, pancreas, prostate, intestine
and immune system [23] and it has been estimated that the VDR can
regulate the expression of as many as 500 of the approximately
20,488 genes in the human genome [24].
ChIP-chip and ChIP-seq analyses have been conducted in target cell
lines to determine the number of DNA binding sites occupied by the
VDR (the cistrome) in the absence and presence of 1α,25(OH)2D3 [25].
These analyses have revealed that despite the potential for 105–106 bind-
ing sites on either themouse or human genomes, less than 1000 sites are
generally occupied by the VDR in the absence of 1α,25(OH)2D3 and
between 2000 and 8000 sites are occupied following treatment with the
hormone. A large percentage of these binding sites also contain RXR,
supporting the view that RXR on a genome-wide scale is indeed a hetero-
dimer partner of VDR. Genomic VDR binding is strongly induced by
1α,25(OH)2D3 in all cells and, more importantly, the sites of binding
within each VDR cistrome differ considerably depending upon cell-type.
The latter observation is consistent with early observations that
1α,25(OH)2D3 regulates the expression of different subsets of genes
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also provide unequivocal support for the idea that in silico analysis cannot
be used as the primary predictor of the presence of a functional VDRE. The
reduction in functional VDR binding sites to a small percentage of those
determined by genomic sequence alone, as determined by direct ChIP-
chip or ChIP-seq analysis, highlights the considerable role of chromatin
structure as a negative regulator of gene expression [28]. ChIP-sequence
data for VDR in immune cells have identiﬁed thousands of VDREs in the
genome but ChIP-sequence identiﬁcation of VDR binding sites is yet to
be determined in other tissue types [29].
3. Micro-RNAs in the endothelium and vitamin D
Micro-RNAs (miRNAs) are non-coding RNAs that regulate gene ex-
pression in a sequence-speciﬁc manner. One study compared HUVECs
(human umbilical vein endothelial cells) treated for 24 h with human
serum albumin and 100 mg/dL glucose (control group), with 200 μg/L
advanced glycated human serum albumin and glucose (250 mg/dL)
(diabetes state) and physiological concentrations of 25(OH)D. miRNA
microarray analysis and real time PCR showed that miR-659 and miR-
510 upregulated in diabetic-like environment were downregulated
after addition of calcitriol and miR-181c, miR-411, miR-126, miR-15a
andmiR-20bwhichwere downregulated in a diabetic like environment
were upregulated [30]. miR-126 is highly enriched in endothelial cells
and is involved in vascular integrity, angiogenesis and wound repair
[31]. In the diabetic-like environment another study using HUVEC also
showed that 1α,25(OH)2D3 decreased expression of genes involved in
the inﬂammatory pathway in the endothelium [32].
4. Endothelium
The endothelium is a complex endocrine and paracrine organ that
plays a crucial role in the maintenance of vascular homeostasis.
Endothelial dysfunction precedes the development of atherosclerotic
changes in large vessels and arteriopathy in small vessels and contrib-
utes to development of atherosclerotic plaques, and stiff, thickened
small vessels in diabetes mellitus [33].
5. The quiescent endothelium
The healthy endothelium responds to physical and chemical signals
by the producing factors that regulate vascular tone, cellular adhesion,
thrombosis, smooth muscle proliferation, and vessel wall inﬂammation
[33].
In normal vascular physiology, nitric oxide (NO) plays a key role in
maintaining the vascular tone, under laminar shear stress in a quiescent
state by inhibition of inﬂammation, cellular proliferation, and thrombo-
sis [34]. The NO is generated by the endothelial isoform of nitric oxide
synthase (eNOS) in its membrane-bound conﬁguration. The released
NO results in S-nitrosylation of a wide range of proteins (inclusive of
NFκB, cell cycle-controlling proteins and proteins involved in the gener-
ation of tissue factor) [35,36] and limits oxidative phosphorylation in
mitochondria [37], thus silencing cellular processeswhichwould other-
wise activate the endothelium [38].
6. The activated endothelium
Endothelial activation represents a switch from a quiescent state
mostly regulated by NO-mediated silencing of cellular processes to an
activated endotheliummediated by redox signaling. Most cardiovascu-
lar risk factors, such as hyperlipidemia, hyperglycemia, hypertension
and smoking are known to activate the molecular machinery in the
endothelium that results in expression of chemokines, cytokines, and
adhesion molecules designed to interact with leukocytes and platelets
and target inﬂammation (Fig. 3) [39]. The eNOS which normally helps
to maintain a quiescent endothelium switches to generate reactiveoxygen species (ROS) as part of endothelial activation. This is termed
eNOS uncoupling and results in superoxide formation or hydrogen per-
oxide (H2O2) formation. The hydrogen peroxide can diffuse rapidly
through cells and react with cysteine groups in cellular proteins to
alter their functions [40]. In chronic conditions like hyperglycemia and
hyperlipidemia, chronic production of ROS may exceed the capacity of
cellular enzymatic and non-enzymatic antioxidants and thus contribute
to vascular disease by sustained endothelial activation [41].
Upon endothelial activation:
1. eNOS uncoupling occurs; ROS such asH2O2will diffuse into the endo-
thelial cell. This leads to expression of adhesive ligands (inclusive of
von-Willebrand factor (vWF) and P-selectin) on the endothelium.
Platelet adhesion also occurs through binding of platelets via
platelet-ﬁbrinogen complexes and intercellular adhesion molecule-
1(ICAM-1). These adherent platelets secrete numerous bioactive
substances that alter the adhesive properties [34].
2. NFκB dissociates from Ikβ (a regulatory protein that inhibits NFκB by
complexing with and trapping it in the cytoplasm) and translocates
into the cell nucleus. Through interactions with CD40, platelets also
release interleukin-1 beta (IL-1 β) which can stimulate endothelial
cells via NFκB to release interleukins, IL-6 and IL-8 and increase the
expression of ICAM-1, VCAM-1, P-selectin and E-selectin. As such
these cytokines and tissue factor release, fuel a feedforward chain
reaction which further decreases NO release [36].
3. The innate inﬂammatory process is triggered. The prolonged interac-
tion between ROS and NO sets up a vicious circle, which results in
further endothelial activation and inﬂammation [34,42].
7. Endothelial injury and repair
Prolonged exposure to cardiovascular risk factors can ultimately
exhaust the protective effect of endogenous anti-inﬂammatory and
antioxidant systems within endothelial cells. Endothelial cells may
then lose their cellular integrity, progress to senescence and detach
into the circulation [43]. The endothelium can repair by replication of
adjacent endothelial cells. Endothelial progenitor cells (EPCs) are also
an important mechanism by which endothelial cells are maintained.
These cells are produced by the bone marrow, circulated in the periph-
eral cells and can differentiate to form mature endothelial cells [44].
Mobilization of these EPCs is in part NO-dependent and thusmay be im-
paired in patients with cardiovascular risk factors such as diabetes
mellitus [45]. The balance between exposure to risk factors and the
capacity for repair is the main determinant of the clinical endothelial
phenotype [42].
8. Prenatal development of endothelium and vitamin D
8.1. Lessons from animal models
In a rat model of maternal vitamin D deﬁciency, hypertension, in-
creased basal tone and endothelial dysfunction have been demonstrat-
ed to stem from a developmental reduction in vitamin D. In this study,
vitamin D-replete and vitamin D-depleted female rats were mated
with vitamin D-replete male rats. The vitamin D-depleted rats were
maintained on vitamin D free diet throughout pregnancy and lactation
and the offspring rats were also maintained on a similar diet. The vita-
min D-depleted female rats and their offspring had a signiﬁcant reduc-
tion in NO and endothelium-derived hyperpolarizing factor(s) (EDHF)-
dependent vasodilatation indicative of vascular endothelial dysfunction
[46]. Nitroprusside-evoked dilatation was unaltered in males but mark-
edly reduced in the vitamin D-depleted female rats [47]. This suggests
that vitamin D alters the basal tone of the endothelium even during de-
velopment. Chronic treatmentwith vitamin D also lowers arterial blood
pressure and reduces endothelium-dependent contractions in the aorta
of the spontaneously hypertensive rat [48].
Fig. 3. Schematic representation of AGEs (Advanced glycation end-products) associated increased oxidative stress induced endothelial activation and lipid peroxidation, formation of foam
cells, smooth muscle migration, formation of fatty streak, thrombus and ﬁbrous cap. The chain of cellular events linking up the vascular smooth muscle cells, endothelial cells and the
monocytes and functional relationships are illustrated (these cells are not endocytosed into the endothelial cell). 1. In the absence of vitamin D and other antioxidants AGEs result in
uncoupling of the NADH oxidase system in the endothelium and increased formation of reactive oxygen species (ROS). 2. This results in oxidation of circulating LDL particles and
endothelial activation. 3. In the early phase mild oxidation of LDL results in the formation of minimally modiﬁed LDL (MM-LDL). MM-LDL stimulates production of MCP-1 that promotes
monocyte chemotaxis. 4. These events lead to monocyte binding to the endothelium and its subsequent binding to the endothelium and its subsequent migration to the subendothelial
space. 5.MM-LDL also stimulates formation of m-CSFwhich promotes the differentiation and proliferation of monocytes intomacrophages. 6. The oxidized LDL particles are subsequently
scavenged bymacrophages (SR-A and CD36+). 7. This results in foam cell formation. 8. There is also an increase in smooth muscle proliferation andmigration into subendothelial space
and together with the foam cells these result in formation of fatty streaks. 9. Oxidized LDL concentration also decreases subsequent eNOS activity and decreases in nitric oxide thus per-
petuating the cycle. 10. The increased reactive oxygen species and decreased nitric oxide lead to a process of continued endothelial activation. 11. The increased ROS in the endothelium
stimulates the NFκB to dissociate from IkB and enter the endothelial cell nucleus and stimulates formation of inﬂammatory cytokines and chemokines, especially IL-6, IL-1B, MCP-1 and
TNF-1α. 12. The NFκB also stimulates expression of cell adhesion markers such as E-selectin, VCAM-1 and ICAM-1 on the endothelial cells. 13. This stimulates the vWF and coagulation
cascade and results in thrombus formation at the fatty streak and further perpetuation of the atherosclerosis process. 14. There is also a stimulation of theVSMCproliferation andmigration
with foam cells increasing fatty streak formation. 15. Many stimuli (angiotensin II and PDGF) are released from the neighboring ECs, monocytes and macrophages. These induce SMC
migration and subsequent proliferation, thereby resulting in the formation of a ﬁbrous cap.
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angiotensin–aldosterone system [49]. In VDR knockout mice, renin ex-
pression and angiotensin II production are increased several folds [49].
Also, mice deﬁcient of the 25(OH)D 1-alpha-hydroxylase gene develop
cardiac hypertrophy and hypertension [49]. Normalization of blood
pressure, cardiac systolic function and renin–aldosterone levels results
with treatment of the 1-alpha-hydroxylase knockout mice with
activated vitamin D [50].8.2. Lessons from human studies
In one study, maternal vitamin D deﬁciency during pregnancy was
associated with lower muscle mass and higher insulin resistance in
offspring at 9 years of age but there was no association with other
cardiovascular markers [51]. In another study, although lower maternal
vitamin D concentration was associated with lower fat mass at birth, it
was associated with greater fat mass at 4 and 6 years [52]. In one
study in which vascular health was assessed with 2D echocardiography
and carotid intima–media thickness (CIMT), no association was seen
between maternal vitamin D status and child outcomes [53]. The small
sample sizes of these studies (178–539 maternal offspring pairs) may
have limited the ability to reveal an association. In a recent large-scale
study (14,541 maternal offspring pairs), an inverse association was
seen between adolescent C-reactive protein (CRP) and apolipoprotein-
B and maternal 25(OH)D concentrations, however there was no differ-
ence in blood pressure and insulin resistance [54]. More large-scale
studies with assessment of endothelial function using ﬂow mediated
dilatation (FMD) and/or EPCs will help to determine the effects of
maternal vitamin D supplementation on the offspring’s endothelium.9. Vitamin D and the endothelium
9.1. Synthesis of 1 alpha,25-dihydroxyvitamin D3 in the endothelium
Synthesis of active form 1α,25(OH)2D3 vitamin D is essential for the
action of vitamin D at the endothelium. The presence of a vitamin D
microendocrine system consisting of a VDR and 1-alpha hydroxylase
enzyme capable of producing 1α,25(OH)2D3 has been demonstrated
in bovine aortic endothelial cells [55]. Expression of mRNA and protein
for 1-alpha-hydroxylase has been demonstrated in the endothelium.
However, there is an important difference in the regulation of this
enzyme at the extra renal sites when compared to renal sites which
is not subject to the exquisite autoregulation observed for this
enzyme in the kidney. Thus endothelial synthesis is dependent on the
availability of 25(OH)D and perhaps the parent compound vitamin D
whichmay have extra-renal effects which are in turn a direct reﬂection
of dietary and environmental access to parenteral vitamin D. In this
study it was also seen to modulate the effect of inﬂammatory cytokines
on the vasculature by promoting leukocyte adhesion [56,57].9.2. Role of vitamin D in the quiescent endothelium
In a recent study it has been seen that 1α,25(OH)2D3 induces a
dose and time-dependent increase in VDR expression and induces
upregulation of VEGF and its receptors as well as antioxidant CuZn-
superoxide dismutase expression in endothelial cells. Hypoxia/
oxidative stress induced downregulation of VDR and CuZn-
superoxide dismutase expression could be prevented by addition of
1α,25(OH)2D3 in culture [58].
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vascular smoothmuscle cell (VSMC) proliferation in quiescent endothe-
lial cells. This increase in proliferation results from a shortening of
the G1 phase. The effect of 1α,25(OH)2D3 on VSMC proliferation is
mediated by an increase in the expression of vascular endothelial
growth factor (VEGF) A, as the inhibition of VEGF activity totally blunted
the 1α,25(OH)2D3-induced VSMC proliferation [59]. 1α,25(OH)2D3 also
induces VSMC migration independent of gene transcription via PI3 ki-
nase pathway [60]. Vitamin D thus contributes to VSMC proliferation,
calciﬁcation and migration in the quiescent endothelium. This increase
in VSMC may be beneﬁcial as in vivo it maybe a way of attenuating the
apoptotic process observed in high resorptive bone conditions pro-
duced with high parathyroid hormones or 1α,25(OH)2D3 levels. These
apoptotic bodies are inducers of vascular calcium deposition [61], and
the increase in proliferation of adjacent VSMC would reduce the space
occupied by the apoptotic bodies and thus the calciﬁed area. VDR ago-
nists have also been shown to have a suppressive effect on VSMC min-
eralization induced by phosphate and tumor necrosis factor-alpha
(TNF-α) and thus have an inhibitory effect on vascular calciﬁcation [62].
9.3. Role of vitamin D in the activated endothelium (Fig. 4)
The effects of vitamin D on endothelial NO production and p38, Akt,
ERK and eNOS were examined in a small in vitro study using HUVEC
cultures. To verify the effects of involvement of VDR in the actionmech-
anism of vitamin D, experiments were repeated in the presence of the
speciﬁc VDR ligands ZK159222 and ZK191784. It was observed
that the vitamin D interaction with VDR caused the phosphorylation
of p38, Akt and ERK leading to eNOS activation and increased NO
formation [63].
Vitamin D works as an antioxidant and it protects the endothelium
from H2O2 oxidant injury through the activation of MEK/ERK-Sirt-1
axis [64]. In a recent study it has also been seen that vitamin D protects
human endothelial cells from oxidative stress through modulation
between apoptosis and autophagy by reducing apoptosis related geneFig. 4. Schematic representation of vitamin D associated effects on the activated endothelium
linking up the vascular smooth muscle cells, endothelial cells and the monocytes and function
1. Vitamin D through interaction with VDR results in an increased activity of antioxidant CuZn-
idase pathways. 2. It enhances eNOS activity and formation of nitric oxide. 3. It increases vascula
It decreases NFκB activity in the nucleuswith decreased formation of Il-6 and decreased express
It attenuates platelet activation and expression of VCAM-1 and production of type 1 trans-mem
into the endothelium. 8. Reduces macrophages and decreases uptake of cholesterol and decreaexpression and enhancing autophagy by activation of pro-autophagic
Beclin 1 and phosphorylation of ERK 1/2 and Akt [65].
Hypoxia/oxidative stress induced downregulation of VDR and
CuZn-superoxide dismutase expression can be prevented by addition
of 1α,25(OH)2D3 in culture [58].
In one study, it has been seen that vascular expression of NFκB was
greater in deﬁcient versus sufﬁcient patients. In the same study
endothelial expression of the downstream proinﬂammatory cytokine
IL-6 was also higher in deﬁcient versus sufﬁcient patients. VDR and
1-alpha-hydroxylase levels were also lower in vitamin D-deﬁcient pa-
tients which could be themolecularmechanism linking the effects [66].
Vitamin D treatment in vitro has been documented to modulate
levels of systemic inﬂammatory cytokines, such as TNF-α and IL-6 as
well as inhibit lipopolysaccharide (LPS) induced activation and vasodi-
latation of vascular endothelium [67]. Moreover, vitamin D treatment
in vitro of HUVEC signiﬁcantly inhibits TNF-α induced VCAM-1and
ICAM-1 expression induced by TNF-α [68]. One clinical study has also
shown vitamin D levels to be inversely associated with levels of 3-
nitrotyrosine and sVCAM-1 indicative of decreased nitrosative stress
and endothelial activation in vitamin D sufﬁcient obese children [69].
In another in vitro study, after a 24-h incubationwith 1α,25(OH)2D3,
HUVECs were stimulated with LPS and incubated in direct contact with
platelets. The expression of CD40L and CD62P in platelets, the expres-
sion of ICAM-1, VCAM-1, the urokinase receptor (uPAR) andmembrane
type 1 matrix metalloproteinase (MT1-MMP) in endothelial cells and
endothelial cell ROS generation were measured by ﬂow cytometry.
The increased expression of VCAM-1 and MT1-MMP in endothelial
cells by proinﬂammatory stimulation with LPS and by direct contact
with activated platelets was signiﬁcantly reduced through pre-
incubation with 1α,25(OH)2D3. Moreover, platelets in direct contact
with pre-incubated endothelial cells showed signiﬁcantly reduced
CD62P expression when compared to platelets incubated with untreat-
ed endothelial cells. 1α,25(OH)2D3 attenuates platelet activation
and the expression of VCAM-1 and MT1-MMP in human endothelial
cells [70].through activation of the nuclear vitamin D receptor (VDR). The chain of cellular events
al relationships are illustrated (these cells are not endocytosed into the endothelial cell).
superoxide dismutase in endothelial cells decreasing the oxidative stress and NADPH ox-
r smoothmuscle proliferation throughVEGF receptors and reduces vascular calciﬁcation. 4.
ion of VCAM-1 and ICAM-1. 5. It also inhibits VCAM-1 and ICAM-1 production by TNF-α. 6.
braneMMP. 7. It suppresses formation of MCP-1 which decreases migration of monocytes
ses in foam cell formation.
10 R. Dalan et al. / IJC Metabolic & Endocrine 4 (2014) 4–171α,25(OH)2D3 has been seen to ameliorate the effects of advanced
glycation end products (AGEs) seen in diabetes mellitus on the endothe-
lial cells by blunting the AGEs-induced elevation of NFκB-p65 DNA bind-
ing activity, a phenomenon related to an increased expression of IkB alpha
as seen in an in vitro study [71]. 1α,25(OH)2D3 also induces increase in
VSMC proliferation through an increase on VEGF expression [59].
It has also been seen that 1α,25(OH)2D3 supplementation in
patients with diabetesmellitus suppressesmacrophage inhibition in re-
sponse toMCP-1 andmRNA expression of chemokine receptor 2 (CCR2)
and the MCP-1 receptor compared to vitamin D-depleted cells. Choles-
terol uptake is also decreased in 1α,25(OH)2D3 supplemented cells.
1α,25(OH)2D3 also suppresses cholesteryl ester formation and
enhances cholesterol efﬂux in macrophages compared to vitamin
D-depleted cells [72].
10. Clinical evidence to link endothelial dysfunction and vitamin
D deﬁciency
Vitamin D deﬁciency has been associated with endothelial dysfunc-
tion in various cross sectional association studies.We have summarized
the most recent studies which have shown an association with 25(OH)
D concentrations (Table 1) [69,73–83]. In these studies, various
methods have been used to measure endothelial function. Endothelial
function can be assessed in clinical studies using brachial artery FMD,
reactive hyperemia index peripherally (RHI-PAT), laser Doppler
ﬂuximetry and iontophoresis. Other surrogate markers of endothelial
function include vascular markers such as E-selectin, vWF, ICAM-1,
VCAM-1, intravascular nitric oxide, and markers of inﬂammation such
as hsCRP. Measurement of EPCs has also been considered a surrogate
measure of endothelial function. All the studies mentioned correlates
with 25(OH)D concentrations. Hence vitamin D insufﬁciency has been
associatedwith higher oxidative stress, higher inﬂammation, higher en-
dothelial activation and resultant endothelial dysfunction clinically.
Data from the FraminghamOffspring Study suggested that aﬁrst cardio-
vascular event is correlated with a low serum level of the metabolically
active form, 1α,25(OH)2D3 [84]. A low serum level of 1α,25(OH)2D3
that is associated with VDR genotypes producing a deﬁciency in the
conversion of 25(OH)D to 1α,25(OH)2D3, was reported to correlate
with the severity of coronary artery disease and left ventricular hyper-
trophy [85]. In the Emory twin study, coronary ﬂow reserve (CFR) was
seen to be signiﬁcantly lower in twins with vitamin D insufﬁciency
compared to the vitamin D sufﬁcient co-twin suggestive of correlations
independent of genetic makeup [73].
11. Clinical evidence for supplementation with vitamin D
Several randomized controlled trials (RCTs) have been conducted in
the last decade to assess whether supplementation with vitamin D
helps to improve endothelial function.Wehave summarized the studies
in Table 2 [80,86–99]. Most of the recent studies done on diverse popu-
lations including patients with recent history of myocardial infarction
(MI), patients undergoing coronary angiogram studies for IHD, patients
with type 2 diabetes mellitus, hypertension and patients with underly-
ing HIV infection on anti-retroviral agents have failed to show an
improvement in endothelial function in the short term. The mode of
replacement of vitamin D is different in all the studies, however there
are negative trials in both regular replacement with vitamin D3 3000–
5000 IU daily and with single or multiple large dose of vitamin D3
(100,000 IU). Various population groups have been studied as well
from African Americans, South Asians, Chinese and Caucasians. In one
study done in African–American population, a signiﬁcant improvement
was seen. It is possible that ethnic groups with higher prevalence of
vitamin D deﬁciency and endothelial dysfunction may beneﬁt more
than other populations. Two studies showed an improvement in PAI-1
and hsCRP suggestive of an improvement in inﬂammation and early
pathways of endothelial function. One of the possible reasons for alack of improvement may also be its acute calciotropic effects which
can cause an increased calcium inﬂux into vascular smooth muscle
and thus increase arterial stiffness in the short term before the effect
of vitamin D supplementation occurs at the vascular smooth muscle
[100,101]. Most of the studies have been done for 12–16 weeks with
only one study being a year long. It is possible that an improvement in
the endothelial function may be seen in the long term if vitamin D con-
centrations are maintained for long durations. At present there are no
long-term studies looking at cardiovascular endpoints as well.
In a recent small RCT (8 healthy adults), the effect of vitaminD status
and subsequent vitamin D supplementation on broad gene expression
was studied [100]. They compared vitamin D supplementation 400 IU
(n = 3) and 2000 IU (n = 5) vitamin D3 daily for 2 months on broad
gene expression in the white blood cells. Interestingly, microarray
analyses showed that improved serum 25(OH)D concentrations were
associated with at least a 1.5-fold alteration in the expression of 291
genes. After vitamin D supplementation the expression of 66 genes,
which was signiﬁcantly different at baseline between the subjects
with 25(OH)D concentrations b20.0 ng/mL (50.0 nmol/L) and 25(OH)
D concentrations N20.0 ng/mL (50.0 nmol/L), was similar in both
groups. In response to vitamin D supplementation, 24 genes decreased
their expression. Notable in terms of endothelial function includes
three genes namely, CD83 (2-fold decrease), TNF-α induced protein 3
(TNFAIP3) (decreased 1.5-fold) and nuclear factor of kappa light poly-
peptide gene enhancer in B-cells inhibitor, alpha (NFκBIA) (1.5-fold).
All these changes in gene expressionmay affect immune and proinﬂam-
matory responses. Itwas seen that any improvement in vitaminD status
improved expression of genes that have a wide variety of biological
functions and that to maximize vitamin D's effect on gene expression
may require even higher doses than 2000 IU of vitamin D3 daily [102].
12. Cardiovascular outcomes and vitamin D deﬁciency
Low plasma concentrations of 25(OH)D have been associated with
vascular and non-vascular mortality [103–110] (See Table 3). In most of
the studies, a non-linear inverse association was seen between 25(OH)
D concentrations and mortality. A reverse J-shaped association was seen
on one large study of 15,099 subjects with a nadir at 32.0 ng/mL
(80.0 nmol/L) [105]. In other inverse associations the risk also seems to
increase at levels b30.0 ng/mL (75.0 nmol/L). Hence it is possible that ex-
cessively high 25(OH)D concentrations may be harmful as well. In one
Chinese population study an association with mortality was not seen,
hence the effect of ethnicity needs to be further determined.
The association between vitaminD status and cardiovascular disease
was examined in a meta-analysis of 19 independent studies which in-
cluded 6123 cases and 65,994 participants. In a comparison of the
highest and lowest 25(OH)D categories, the pooled relative risk (RR)
(95.0% CI) was 1.53 (1.30–1.77) for total CVD 1.42 (1.19–1.71) for
CVD mortality, 1.38 (1.21–1.57) for coronary heart disease and 1.64
(1.27–2.10) for stroke. The associations remained strong and signiﬁcant
when analyses were limited to studies that excluded participants with
baseline CVD and were better controlled for season and confounding.
The CVD risk increased monotonically across decreasing serum
25(OH)D concentrations below 24.0 ng/mL (60.0 nmol/L) with a RR
(95.0% CI) of 1.03 (1.00–1.06) per 10.0 ng/mL (25.0 nmol/L) decrement
in 25(OH)D. There was no clear decrease or increase in CVD risk for
serum 25(OH)D N24.0 ng/mL (60.0 nmol/L) based on the few data
points available [111]. Recently in a cohort study done by Dror Y et al.,
involving 422,822 subjects, it was seen that compared to those with
20.0–36.0 ng/mL (50.0–90.0 nmol/L), the adjusted hazard ratios
among those with levels b10.0 ng/mL (25.0 nmol/L), 10.0–20.0 ng/mL
(25.0–50.0 nmol/L) , and N36.0 ng/mL (90.0 nmol/L) were 1.88 (CI:
1.80–1.96), 1.25 (CI: 1.21–1.30) and 1.13 (CI: 1.04–1.22) respectively
[112]. However the sample size for N36.0 ng/mL (90.0 nmol/L) was
small, hence ﬁrm conclusions could not be derived from that study.
This relationship although reported as a U-shaped relationship by the
Table 1
Studies looking at association between endothelial function and 25(OH)D concentrations.
Reference No. of subject Characteristics Mean 25(OH)D concentrations Percentage of patients
with low 25(OH)D
Method used to measure
Endothelial Function (EF)
Associations seen
73. 368 Middle aged male twins 37.0 ng/mL
(80.0 nmol/L)
45.0% twins
(b30.0 ng/mL)
CFR CFR was signiﬁcantly lower in vitamin D insufﬁ-
cient subjects (2.41 vs 2.64, p = 0.007). In twin
pairs CFR was also signiﬁcantly lower in vitamin D
insufﬁcient co-twin (2.35 vs 2.58; p = 0.037).
74. 31 Hypercholesterolemic patients
with Vitamin D insufﬁciency
(b30.0 ng/mL (75.0 nmol/L))
b30.0 ng/mL
(75.0 nmol/L)
100%
(b30.0 ng/mL)
Basal nitric oxide activity e
renal vasculature before a fter
blockade of NO synthases h
systemic infusion NG-
monomethyl-L-arginine
(L-NMMA)
25(OH)D concentration correlated with basal nitric
oxide (β = −0.446, p = 0.015).
75. 222 Patients with IHD who underwent
coronary angiogram
31.8 ng/mL
(80.0 nmol/L)
47.0%
(b30.0 ng/mL)
Coronary blood ﬂow and b hial
artery FMD
Vitamin D insufﬁciency correlated with % FMD
(β = 0.424) and CIMT (β = 0.43) (p b 0.001).
76. 70 Patients with diabetic
nephropathy
In non-deﬁcient group: 28.0 ng/mL
(69.4 nmol/L);
In deﬁcient group: 17.0 ng/mL
(42.1 nmol/L)
43.0%
(b50.0 nmol/L)
Laser Doppler Fluximetry
Iontophoresis
Endothelium dependent vasodilation was lower in
the vitamin D deﬁcient group (23.6 vs 37.3,
p = 0.004).
77. 100 Indian patients undergoing
coronary angiogram for IHD
14.8 ng/mL
(37.0 nmol/L)
80.0%
(b30.0 ng/mL)
% brachial artery
FMD
Lower 25(OH)D concentrations were associated
with lower FMD (FMD 4.57% vs 10.68%; p b 0.001).
69 66 Obese Caucasian children
7–14 years
24.3 ng/mL (60.7 nmol/L) in obese and
30.0 ng/mL (75.0 nmol/L) in normal BMI
30.0%
(b20.0 ng/mL)
3-nitrotyrosine and sVCAM Inverse relationship of 25(OH)D concentration to
3-nitrotyrosine (r = −0.424, p = 0.001) and
sVCAM-1 (r = −0.272, p = 0.032).
78 56 Normal Turkish women 21.32 ug/L
(53.2 nmol/L)
59.0%
(b20.0 mcg/L)
RHI-PAT RHI correlated with 25(OH)D concentrations
(β = 0.401, p = 0.002).
79 23 African Americans and
22 European Americans
Healthy African Americans and
European Americans
21.9 ng/mL
(55.0 nmol/L)
51.0%
(b30.0 ng/mL)
Central aortic pressure, pu
wave velocity, augmentat
index and FMD
25-OH D concentrations correlated with Augmen-
tation index (r = −0.35, p = 0.002), Pulse wave
velocity (r = −0.39, p = 0.009) and FMD
(r = 0.37, p = 0.01).
80 554 Healthy adults 31.8 ng/mL
(80.0 nmol/L)
47.0%
(b30.0 ng/mL)
Brachial artery FMD and R PAT,
carotid–femoral pulse wa
velocity, augmentation in
subendocardial viability r
25(OH)D concentration correlated with pulse wave
velocity (β = −0.09; p = 0.001), Augmentation
index (β = −0.1; p = 0.03) and RHI (β = −0.23;
p b 0.001).
81 280 Chinese Patients with type 2 DM 25.0 ng/mL
(62.4 nmol/L)
34.3%
(b20.0 ng/mL)
EPCs (CD34+/KDR+) and
brachial artery FMD
Vitamin D deﬁcient patients had lower FMD (Mean
difference = −1.43%, p = 0.001) and CD133+/
KDR + EPC counts (mean difference = −0.12%,
p = 0.022).
82 41 Healthy adults NA NA EPCs (CD34+/KDR+) Positive correlation between 25(OH)D
concentrations and EPCs.
83 253 Normal population cohort aged
51–77 years
28.9 ng/mL (72.2 nmol/L) NA Asymmetric dimethylargi and
C-reactive protein concen ions
25(OH)D concentrations correlated with
asymmetric dimethylarginine (β = 0.19;
p = 0.03) and CRP concentrations (β = 0.14;
p = 0.03).
25(OH)D: 25-hydroxyvitamin D; CFR: Coronary Flow Reserve; CIMT: Carotid Intima–media thickness; CRP: C-Reactive Protein; DM: Diabetes Mellitus; EF: Endothelial Function; E : Endothelial Progenitor Cells; FMD: Flow Mediated Dilatation;
IHD: Ischemic Heart Disease; L-NMMA: NG-monomethyl-L-arginine; NA: Not Applicable; NO: Nitric Oxide; RHI-PAT: Reactive Hyperemia Index–Peripheral Arterial Tone; sVCAM- rum Vascular Cell Adhesion Molecule-1.
Note. This article is not an all-inclusive systematic review; this table may not list all studies looking at association between endothelial function and 25(OH)D concentrations.
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Table 2
Randomized controlled trials looking at endothelial function before and after vitamin D supplementation.
Reference No of subject Characteristics Mean Baseline 25(OH)D
concentration ng/mL (nmol/L)
Design of study Intervention/ Duration Primary Endpoint Improvements seen
86 68 Patients with BP N140/90 mmHg
on more than three antihyperten-
sive agents
16.8 ng/mL
(42.0 nmol/L)
Parallel group, double
blind RCT
100,000 IU oral vitamin D3 or
matching placebo every 2 months
for 6 months
Ofﬁce and 24 h ambulatory blood
pressure and ventricular mass
No signiﬁcant change in blood
pressure or ventricular mass.
87 50 South Asian women with low
25(OH)D concentrations
(b30.0 ng/mL (75.0 nmol/L))
10.8 ng/mL
(27.0 nmol/L)
Double blind, placebo
controlled RCT
Single dose of 100,000 IU oral
vitamin D3 or matching placebo
Brachial artery FMD;
Outcomes measured at baseline,
4 and 8 weeks
No signiﬁcant change in FMD, but
PAI-1 and tissue plasminogen
activator levels decreased in the
intervention group at 8 weeks.
.88 100 Type 2 DM with low 25(OH)D
concentrations (b30.0 ng/mL
(75.0 nmol/L))
21.1 ng/mL (52.7 nmol/L) in the
intervention arm and 21.9 ng/mL
(54.6 nmol/L) in the placebo arm
Double blind, placebo
controlled RCT
Vitamin D3 5000 IU/day for
12 weeks
Brachial artery FMD, and EPC
count, oxidative markers
No signiﬁcant change seen in any
markers or brachial artery FMD.
89 159 Patients (older than 70 years)
with isolated systolic
hypertension and 25(OH)D
concentrations lower than
30.0 ng/mL (75.0 nmol/L)
18.0 ng/mL
(44.9 nmol/L)
Double blind, placebo
controlled RCT
A total of 100,000 IU of oral
cholecalciferol or matching
placebo every 3 months for
1 year.
Brachial artery FMD, carotid–fem-
oral pulse wave velocity (PWV),
and aortic augmentation index
(AIx)
No signiﬁcant change.
90 75 Patients with history of MI 19.6 ng/mL (49.0 nmol/L) in the
intervention arm and 18.0 ng/mL
(45.0 nmol/L) in the placebo arm
Double blind, placebo
controlled RCT
100,000 IU of oral vitamin D2 at
baseline, 2 months and 4 months
RHI-PAT, CRP, vWF No improvement in RHI. An
improvement seen in CRP.
.91 58 Patients with history of stroke and
baseline 25(OH)D less than
30.0 ng/mL (75.0 nmol/L)
15.5 ng/mL (38.7 nmol/L) in the
intervention arm and 15.1 ng/mL
(37.8 nmol/L) in the placebo arm
Double blind, placebo
controlled RCT
100,000 IU of oral vitamin D2 or
placebo at baseline, 8 weeks and
16 weeks
Brachial artery FMD at 8 weeks
and 16 weeks.
Yes at 8 weeks,
No at 16 weeks.
92. 114 Postmenopausal women with
25(OH)D concentration between
10.0 and 60.0 ng/mL (25.0–
150.0 nmol/L)
32.3 ng/mL (80.6 nmol/L) in the
intervention arm and 30.3 ng/mL
(75.6 nmol/L) in the placebo arm
Double blind, placebo
controlled RCT
Vitamin D3 2500 IU or placebo,
daily for 4 months
Brachial artery FMD, carotid–
femoral pulse wave velocity
(PWV), and aortic augmentation
index (AIx) and CRP
No
93. 65 Peripheral arterial disease and
vitamin D deﬁciency
16.3 ng/mL (40.7 nmol/L) in the
intervention arm and 17.0 ng/mL
(42.4 nmol/L) in the placebo arm
Double blind, placebo
controlled RCT
Single dose of 100,000 IU vitamin
D3 or placebo
Brachial artery FMD, coagulation
and inﬂammation parameters
No
94. 45 HIV infected patients with 25(OH)
D concentration b20.0 ng/mL
(50.0 nmol/L)
Double blind, placebo
controlled RCT
Vitamin D3 4,000 IU daily or
placebo for 12 weeks
Brachial artery FMD No
95 90 Coronary artery disease and
vitamin D deﬁciency
(20.0 ng/mL (50.0 nmol/L))
13.0 ng/mL (32.4 nmol/L) in the
intervention arm and 14.0 ng/mL
(35.0 nmol/L) in the placebo arm
Double blind; placebo
controlled, wait list
control design
50,000 IU oral ergocalciferol or
placebo
RHI-PAT No
80 42 Healthy adults 31.8 ng/mL
(79.4 nmol/L)
Open label 6 months, goal to normalize
vitamin D levels
RH-PAT, pulse wave velocity,
augmentation index and
subendocardial viability ratio
There was a signiﬁcant
improvement in RHI-PAT and
subendocardial viability ratio.
96 57 African American adults 13.7 ng/mL (34.3 nmol/L) in the
intervention arm and 15.3 ng/mL
(38.2 nmol/L) in the placebo arm
Double blind, placebo
controlled, wait list
control design
Vitamin D3 2000 IU per day for
16 weeks or placebo
Brachial artery FMD Signiﬁcant improvement was seen
in the brachial artery FMD
(1.8 + −1.3%).
97 61 Type 2 DM and baseline 25(OH)D
b40.0 ng/mL (100.0 nmol/L)
18.0 ng/mL (45.0 nmol/L) in the
intervention arm and 16.4 ng/mL
(41.0 nmol/L) in the placebo arm
Randomized, parallel
group, placebo
controlled
Placebo, 100,000 IU vitamin D2,
200,000 IU vitamin D
Brachial artery FMD An improvement seen in systolic
blood pressure and BNP but no
change in FMD.
98 23 25(OH)D b25.0 ng/mL
(62.4 nmol/L)
10.0 ng/mL (20.4 nmol/L) in the
intervention arm and 30.0 ng/mL
(75.1 nmol/L) in the control arm
Open label prospective
comparative study
300,000 IU of vitamin D2 monthly
for 3 months
Brachial artery FMD 3.4% improvement in the FMD
after treatment.
99 34 Type 2 DM patients 16.1 ng/mL (40.2 nmol/L) in the
intervention arm and 14.5 ng/mL
(36.2 nmol/L) in the placebo arm
Double blind; parallel
group; placebo
controlled
Single dose 100,000 IU vitamin
D2/placebo
8 weeks
Brachial artery FMD 2.3% improvement in brachial
artery FMD after treatment.
25(OH)D: 25-hydroxyvitamin D; AIx: Augmentation Index; BNP: B-type Natriuretic Peptide or Ventricular Natriuretic Peptide; CIMT: Carotid Intima–media thickness; CRP: C-Reactive Protein; DM: Diabetes Mellitus; EPCs: Endothelial Progenitor
Cells; FMD: Flow Mediated Dilatation; IHD: Ischemic Heart Disease; MI: Myocardial Infarction; PAI-1: Plasminogen Inhibitor Activator-1; RCT: Randomized Controlled Trial; RHI-PAT: Reactive Hyperemia Index–Peripheral Arterial Tone; sVCAM-
1: serum Vascular Cell Adhesion Molecule-1; vWF: von-Willebrand Factor.
Note. This article is not an all-inclusive systematic review; this table may not list all randomized controlled trials looking at endothelial function before and after vitamin D supplementation.
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Table 3
Association of 25(OH)D concentrations with mortality.
Reference Study Design Patient Population No. of patient Duration of
follow up
Association seen
103 Prospective 1:1 case control
study nested with EuroSIDA
cohort
HIV-infected persons 250 2–6 years Odds of death decreased by 46.0% for a two-fold
increase in latest 25(OH)D concentrations.
104 Prospective Adult Swiss Population 3404 10 years Per 10.0 ng/mL (25.0 nmol/L) increase in 25(OH)D,
all-cause mortality decreased by 20.0%.
105 Prospective NHANES III population
(1988–1994)
15,099 15 years Reverse J-shaped association was seen with nadir of
risk at 32.0 ng/mL (81.0 nmol/L).
106 Cohort-Prospective German Population based
cohort aged 50–74 years
9578 at baseline and
5469 at 5 years
9.5 years (median) The hazard ratio for vitamin D b12.0 ng/mL (30.0 -
nmol /L) was signiﬁcantly increased 1.71, vitamin D
between 12.0 and 20.0 ng/mL (30.0–50.0 nmol/L)
was 1.17 compared with vitamin D concentration
N20.0 ng/mL (50.0 nmol/L).
Association was non-linear with risk beginning to
increase at 25(OH)D concentrations b30.0 ng/mL
(75.0 nmol/L).
107 Meta-analyses of 12 studies Elderly study participants 32,142 A 8.0 ng/mL (20.0 nmol/L) increase in 25(OH)D
concentrations was associated with 8.0% lower
mortality in general elderly population.
108 Prospective study and
comparison with meta-
analyses
Elderly UK men and
meta-analyses
5,409 13 years After adjustment with other variables a doubling in
25(OH)D concentrations resulted in 20.0% lower
vascular and 23.0% lower non-vascular mortality.
109 Cohort-Prospective Chinese population in China 1,101 24 years No association with all-cause mortality or speciﬁc
cause mortality.
110 Observational prospective White population 1,621 11 years (median) The association with composite outcome (Incident
hip fracture, MI, cancer or death) varied by season
with 24.0% higher risk at season speciﬁc z score of
lower than−0.54.
25(OH)D: 25-hydroxyvitamin D; HIV: Human Immunodeﬁciency Virus; MI: Myocardial Infarction; NHANES III: Third National Health and Nutrition Examination Survey.
Note. This article is not an all-inclusive systematic review; this table may not list all studies looking at association of 25(OH)D concentrations with mortality.
13R. Dalan et al. / IJC Metabolic & Endocrine 4 (2014) 4–17authors was actually a reverse J-shaped association as the increase in
hazard risk above 36.0 ng/mL (90.0 nmol/L) was modest and there
was no evidence of a dose–response relationship at higher levels
[113]. The non-linear association has also been corroborated in other
large-scale studies as well [114–116].
The above studies all suggest that there is likely a reverse J-shaped
association of serum 25(OH)D concentrations and cardiovascular risk
and mortality with the lowest risk being at 20.0–40.0 ng/mL (50.0–
100.0 nmol/L). The reasons for a reverse J-shaped association remain
unclear. The main activity of vitamin D is attributed to the absorption
of calcium which in high concentrations may accelerate intravascular
calciﬁcation and the deleterious effects of high concentrations may be
secondary to this [117].Table 4
Some randomized controlled trials using vitamin D as intervention with assessment of CVD as
Reference Study Design/
Patient Population
Primary Outcome Secondary
Outcome
Sample size/
patient age
121 RCT/Healthy
postmenopausal
women
Hip fractures Risk of CHD 36,282 women
aged 50–79 yea
122 RCT/Normal UK
population
Fracture incidence
and total mortality
CVD 2686 participan
(2037 men and
women)
123 RCT Fractures Coronary
mortality
327 patients
(57 men and 27
women, N65 ye
124 2 × 2 factorial
RCT
Mortality, vascular
disease or cancer
5292 patients
(85.0% women
25(OH)D: 25-hydroxyvitamin D; CHD: Coronary Heart Disease; CVD: Cardiovascular Disease; M
Note. This article is not an all-inclusive systematic review; this table may not list all randomize
outcome.An association of low serum 25(OH)D concentrations with a higher
risk of stroke has also been seen in one prospective studies and meta-
analyses [112,118]. Serum 25(OH)D concentrations have also been
found to be a prognostic marker for death and functional outcomewithin
90 days in Chinese patients with acute ischemic strokes [119]. In another
cohort study of 24,094 adult patients that aimed to look at the association
between pre-hospital serum 25(OH)D and risk of mortality, it was
seen that serum 25(OH)D concentrations b20.0 ng/mL (50.0 nmol/L)
and N =60.0 ng/mL (150.0 nmol/L) before hospitalization were associ-
ated with increased odds of 90-day mortality [120].
Thus far, RCTs have not been able to conﬁrm or refute the beneﬁt of
vitaminD supplementation on vascularmortality. Fewprospective RCTs
evaluating the effects of vitamin D supplementation on CHD have beensecondary outcome.
Length of follow
up
Dose of Vitamin D Outcome related to CHD
rs
7 years of follow
up
500 mg calcium + 200 IU
vitamin D3 twice daily
No beneﬁcial CHD events.
ts
649
5 years 100,000 IU vitamin D3 4
monthly
No beneﬁcial CHD events.
0
ars)
9 months Possible combinations of
3 g calcium carbonate,
1000 IU vitamin D3,
2.5 mg methandienone
and or placebos
Coronary mortality higher
among those taking all
three active substances.
)
24–62 months
with follow up
3 years
thereafter
Daily vitamin D3 800 IU,
calcium 1000 mg, both or
placebo
No signiﬁcant difference
was seen. Subgroup
analyses suggested beneﬁt
in patients on vitamin D3
only.
I: Myocardial Infarction; RCT: Randomized Controlled Trial.
d controlled trials using vitamin D as intervention with assessment of CVD as secondary
Table 5
Meta-analyses of randomized controlled trials using vitamin D.
Meta-analyses
reference
Total no of studies
analyzed
Total no. of subjects/Age/
Demographics
Baseline 25(OH)D
concentrations
Vitamin D doses used Duration of
follow up
Cardiovascular risk reduction
125 51 trials up to
August 2010
Average age 37–87 years,
most studies involved
women and/or elderly
patients
14 trials included only patients
with vitamin D deﬁciency
(b20.0 ng/mL (50.0 nmol/L))
Only 1 study used dose
of 2000 IU of vitamin
D3 per day.
2 studies used 1000 IU
of D3 per day.
1–5 years No signiﬁcant effect on
mortality.
No signiﬁcant effect on
cardiovascular risk of MI and
stroke (only 6 trials analyzed
for this)
126 56 trials which
reported mortality
95,286 subjects Dose of 300 IU to
50,000 IU of vitamin D
per day.
Median dose of 800 IU
1–7 years Decreased all-cause mortality
in institutionalised elderly
patients
127 42 trials 1992–2012 85,466 subjects, average
age 37–89 years, most
studies involved women
and elderly patients
22 trials include patients with
vitamin D deﬁciency
(b20.0 ng/mL (50.0 nmol/L))
300–3333 IU per day 29 RCTs
b3 years
Decrease in cancer mortality
seen but no signiﬁcant
decrease in cardiovascular
mortality.
128 40 trials 48,647 patients 23 (72%) had patients with
vitamin D deﬁciency
(b20.0 ng/mL (50.0 nmol/L))
200–9000 IU per day 1 month to
7 years
No signiﬁcant decrease in
cardiovascular mortality
129 18 RCTs 57,311 subjects In 16 trials patients with
vitamin D deﬁciency
(b20.0 ng/mL (50.0 nmol/L))
300–2000 IU per day
(only one trial used
2000 IU, others used
800 IU or lower)
5.7 years 7.0% lower mortality was seen.
25(OH)D: 25-hydroxyvitamin D; MI: Myocardial Infarction; RCT: Randomized Controlled Trial.
Note. This article is not an all-inclusive systematic review; this table may not list all meta-analyses of randomized controlled trials using vitamin D.
14 R. Dalan et al. / IJC Metabolic & Endocrine 4 (2014) 4–17conducted and currently none of the prospective trials have pre-
speciﬁed CHD as a primary outcome (Table 4) [121–124]. No beneﬁcial
effects of vitamin D supplementation of coronary heart disease or stroke
were reported in the Women’s Health Initiative (WHI) trial, in
which 36,282 post-menopausal women were randomized to 400 IU
vitamin D3 versus placebo [121]. In the RECORD trial of 5292
older people randomized to 800 IU vitamin D3 versus placebo,
there is no evidence of beneﬁcial effect on mortality or vascular disease
[124].
Multiple systematic analyses andmeta-analyses have been conduct-
ed in the last few years to look at RCTs using vitamin D as intervention
(Table 5) [125–129]. In all the meta-analyses, although many studies
had patients with baseline vitamin D deﬁciency, most studies used
only up to 800 IU of vitamin D3 daily with very few studies using
more than 2000 IU of vitamin D daily. The duration of follow up is also
less than 7 years with most studies being shorter than 3 years. No sig-
niﬁcant decrease in cardiovascularmortalitywas seen in these analyses,
although some of the pooled analyses did show a decrease in all-cause
mortality especially in elderly and institutionalized patients.
It has also been suggested that the skin by itself is a signiﬁcant source
of NO-related species that can bemobilized by sunlight (UVA radiation)
and delivered to the systemic circulation to exert coronary vasodilator
and cardio-protective effects [130]. UVA irradiation of skin in vitro
leads to photodecomposition of NO stores and release of NO [131].
Skin is the largest organ in the body and all three NOS isoforms are
expressed in the dermis and epidermis, and in addition to this, nitrite
and NO are generated on the skin surface by reduction of sweat nitrate
and also oxidation of ammonia. UVA irradiation can increase plasma ni-
trite levels by 40.0% [132]. Hence, it is possible that ultraviolet irradia-
tion from sunlight exposure (which increases 25(OH)D levels and
promotes NOmobilization from the skin)mayprovide better protection
against CVD when compared to oral vitamin D supplementation.13. Conclusion
Vitamin D deﬁciency has been associated with endothelial dysfunc-
tion and CVD. Vitamin D is seen to be useful in maintaining the
quiescent endothelium and is able to modulate or affect certain stages
of the activated endothelium to reverse the activated stage and in therepair of the damaged endothelium in vitro and in vivo studies. There
aremany cross sectional studies showing a positive correlation between
endothelial dysfunction and vitamin D deﬁciency. However, most re-
cent RCTs of vitamin D supplementation have failed to show an im-
provement in endothelial function in the short term. Longer term
RCTs using doses of vitamin D to optimize 25(OH)D concentrations to
20.0–40.0 ng/mL (50.0-100.0 nmol/L) or using vitamin D analogues
with no calciotropic effects to assess endothelial function and cardiovas-
cular outcome in various populations including all age groups are need-
ed. The effect of UVA radiation on endothelial function also needs to be
studied.
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